Becton, Dickinson and Company (BD) and Ypsomed have announced an expansion of their partnership with the development of a 5.5ml version of the BD Neopak XtraFlow glass prefillable syringe.
The new syringe is designed for full compatibility with Ypsomed’s YpsoMate 5.5 autoinjector platform, aiming to provide additional options for pharmaceutical companies and patients requiring large volume subcutaneous self-injections.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The syringe also incorporates BD’s advanced manufacturing technologies, including thinner wall cannulas and a shorter 8mm needle.
These features are intended to facilitate the delivery of medicines with higher volumes and viscosities, enabling quicker injection times and improved flow.
Large volume subcutaneous injections, greater than 1ml, are increasingly common for treating autoimmune diseases, oncology, metabolic disorders, and rare diseases.
Introduced in 2022, the YpsoMate 5.5 was created to address this requirement, featuring an ergonomic design, straightforward two-step activation, and clear feedback features aimed at supporting patient confidence.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe new syringe is intended to further enhance the YpsoMate 5.5 autoinjector by improving flow efficiency and shortening injection times as both dosing volumes and medication viscosities rise.
BD and Ypsomed previously worked together on the BD Neopak XtraFlow 2.25ml glass prefillable syringe and the YpsoMate 2.25 autoinjector.
The newly developed 5.5ml version extends this platform, aiming to expedite the development of combination products and reduce time-to-market for pharma companies.
The BD Neopak XtraFlow 5.5ml glass prefillable syringe remains under development and will be subjected to thorough testing to ensure it is compatible with the YpsoMate 5.5 platform. Feasibility study samples are anticipated to be available by mid-2026.
BD Pharmaceutical Systems worldwide president Patrick Jeukenne said: “This next-generation syringe is a direct response to the growing demand for patient-friendly solutions in the high-dose biologics space.
“By combining BD’s expertise in drug delivery with Ypsomed’s leadership in autoinjector platforms, we are helping to simplify self-injection for patients managing complex conditions.”
In November 2025, BD secured 510(k) clearance from the US Food and Drug Administration and received CE marking under the European Union In Vitro Diagnostic Regulation for its bacterial panels designed for use on the BD COR System.
